Skip to main content
AVLN logo

AVLN · Avalyn Pharma Inc.

Track AVLN — free
$28.41 -0.30 (-1.03%)
Market Cap
$1.28B
Shares
44.52M
Volume · Nov 20 38.58K Avg daily vol (3M) 349.44K

Price & Indicators

 

Key stats

Close
$28.70
Thu 19 Nov
Open
$27.86
Thu 19 Nov
Average volume, 30 days
435K
shares a session
Short interest
2.3M
5.2% of shares · 5.3 days to cover
Day range
$27.01$28.90
Open $27.86 Close $28.70
Available closing range
$23.33$39.25
Close $28.70 26.9% under the high
Short volume, last session
95%
Last earnings
Jun 3, 2026
Latest filing
10-Q · Nov 12
Price history
Apr 2026 to Nov 2026

The closing range uses available history since Apr 30, 2026; less than a full year is stored.

Latest documents

2026
Nov 18
Investor event
Inhaled APO1 completes enrollment in 52-week Phase 2b study

Avalyn Pharma said its inhaled perfenidone, APO1, completed enrollment in a large global Phase 2b study over the summer, with 52-week data expected in the second half of next year. Its base case is another Phase 3 study before approval. Inhaled nintetanib, APO2, has a 12-week proof-of-concept study with data expected late in 2027.

6 source passages
We have a drug, the inhaled profanedone, APO1, that completed enrollment in a large global Phase 2b study over the summer. It's a 52-week study, so we'll have data back from that in the second half of the year next year. But I think the most conservative plan, the one that we're assuming is our base case, is that we'll have another Phase 3 to do after this for approval. We also have a Phase 2 ongoing for our inhaled nintetinib, that's APO2, Another global phase two study. That one's more of a proof of concept, 12-week study. We think we'll have data back from that program late in 2027. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss reaches $85.5 million with runway into 2029

Avalyn Pharma reported a nine-month net loss of $85.5 million and $386.6 million in cash, cash equivalents and marketable securities as of September 30, 2026, which it expects to fund operations into 2029.

Net loss $29.66M Diluted EPS -$0.67
Read from the MD&A section
4 source passages
References to the "Company," “Avalyn,” “Avalyn Pharma” “we,” “our,” “us,” or similar terms refer to Avalyn Pharma Inc. including net losses of $29.7 million and $23.6 million for the three months ended September 30, 2026 and 2025, respectively, and net losses of $85.5 million and $61.3 million for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, we had cash, cash equivalents, and marketable securities of $386.6 million. We believe, based on our current operating plans, that our cash, cash equivalents and investments in marketable securities will enable us to fund our operating expenses and capital expenditures into 2029. Open the document at this passage
Nov 12
Current report 8-K
AP03 Phase 1 started; cash runway projected into 2029

Avalyn Pharma Inc. started a Phase 1 study of AP03 in healthy volunteers. It had $386.6 million in cash, cash equivalents and marketable securities on September 30, 2026, with runway projected into 2029; third-quarter net loss was $29.7 million.

Financial results
4 source passages
BOSTON, MA, November 12, 2026 -- Avalyn Pharma Inc. (Avalyn or the Company, Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases today announced financial results for the third quarter ended September 30, 2026 and recent business highlights. Initiated Phase 1 Trial of AP03 in Healthy Volunteers. Cash, cash equivalents, and marketable securities were $386.6 million as of September 30, 2026. The Company’s current cash, cash equivalents, and marketable securities are projected to be sufficient to fund operations into 2029. Net loss: Net loss was $29.7 million for the third quarter of 2026, as compared to $23.6 million for the third quarter of 2025. Open the document at this passage
Nov 10
Investor event
Avalon says cash supports pipeline into 2029

Avalon said around $400 million of cash extends its runway into 2029, assuming Phase 3 funding for AP01 and AP02. The inhaled profenidone MIST study enrolled 398 patients with progressive pulmonary fibrosis.

5 source passages
Avalon is a clinical stage company. Cash takes us just around $400 million. That takes us into 2029 with the key assumption that our base case will be funding a Phase 3 for AP01 and a Phase 3 for AP02. So the MIS study that you mentioned is our APO-1 inhaled profenadone phase 2B study, designed to be a 375-patient study, but we over-enrolled it. So we completed enrollment ahead of schedule and then over-enrolled. So it's 398 patients in that study. And our MIST study, which is the one that's ongoing now, we think will hopefully really give us powerful data to be able to move the program forward. We're doing it in the sort of second indication in the space, which is called progressive pulmonary fibrosis, or PPF. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$312.64M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3,725.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.2%
Latest settlement · 5.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 50-day avg +2%
above
RSI (14) 52
neutral
MACD trend Positive
52-week position 34%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Very Strong
1-month return +5%
trailing
6-month return +8%
trailing
Relative strength +13%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+25% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.17% of shares out · ▼ -2.2% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
116 holders — 13F breadth
Squeeze score 74
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 64%
annualized · 1-yr
Max drawdown −41%
past year
ATR 7.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
+2% Bullish
RSI (14)
52 Neutral
MACD trend
Positive Bullish
52-week position
34% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+25% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.17% of shares out · ▼ -2.2% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
116 holders — 13F breadth
Price context
position in its available closing range
Range low $23 Now $29 · 34% Range high $39
vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and marketable securities $413.5M Second Quarter 2026 —
Net proceeds from initial public offering $316.6M Second Quarter 2026 —
Patients randomized in MIST Phase 2b trial 398 Second Quarter 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AVLN
Avalyn Pharma Inc.
this stock
$1.28B — — — 5.2%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
116
% held
103.7%
Net QoQ
+1.9M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
136
View
Short & Settlement
Short Interest Falling
Shares short
2.3M
Days to cover
5.3d
Change
-52.1K sh
View
Short Volume
Short vol %
95%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
430.8K
Value
$11.1M
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
18

Avalyn Pharma said its inhaled perfenidone, APO1, completed enrollment in a large global Phase 2b study over the summer, with 52-week data expected in the second half of next year. Its base case is another Phase 3 study before approval. Inhaled nintetanib, APO2, has a 12-week proof-of-concept study with data expected late in 2027.

View
Proposed Sales
Value
$1.6M
Shares
53.2K
Filed
Nov 17, 2026
View
Exempt Offerings
Offering
$189.2M
Filed
Oct 10, 2023
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Avalyn Reports Third Quarter 2026…
Published
Nov 12, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
AVLN -6.2% +5.3% +7.7% +12.0% —
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -0.7% +11.6% +13.3% +17.3% —
Key facts CIK 1540171 CUSIP 05348Y105 13F (30d) 112 filings 110 filers Visit website Investor relations